Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The SKOV and SKOV TR cells were exposed to
2022-12-09

The SKOV3 and SKOV3TR Shikonin were exposed to stepwise increased concentration of paclitaxel with or without a different concentration of autophagy inhibitor (3-MA or HCQ) to further evaluate whether suppression of autophagy affected the growth and drug sensitivity of ovarian cancer cells in vitro
-
br Contemporary understanding for alcoholic cardiomyopathy U
2022-12-09

Contemporary understanding for alcoholic cardiomyopathy Up-to-date, a number of theories are postulated for alcoholic cardiomyopathy including generation of mitochondrial reactive oxygen species (ROS), oxidative stress, neurohormonal overactivation (catecholamines and angiotensin II), apoptosis a
-
NOXA a BH only protein is
2022-12-09

NOXA, a BH3-only protein, is best known as a selective inhibitor of MCL-1, which is a highly expressed pro-survival protein in many human malignancies [30]. In addition, NOXA was recently proven to act as a direct activator via directly binding to BAX to induce apoptosis [31]. Given that its levels
-
Two critical determinants of receptor trafficking are found
2022-12-09

Two critical determinants of receptor trafficking are found within the GABAB1 cytoplasmic tail: the di-leucine internalization signal (EKSRLL) (Margeta-Mitrovic et al., 2000, Restituito et al., 2005) and the ER retention signal (RSRR) (Calver et al., 2001, Margeta-Mitrovic et al., 2000, Pagano et al
-
Several strategies have been employed to
2022-12-09

Several strategies have been employed to design and engineer peptide biosensors of kinase activity, which are quite different from the strategies developed to generate genetically encoded KARs. In all cases, lpl receptor induces changes in the spectral properties of the fluorophore(s) incorporated i
-
br HIF Signaling in AA Therapy Resistance
2022-12-09

HIF-α Signaling in AA Therapy Resistance An important result emerging from Phase 3 clinical trials testing AA therapies is improvement of progression-free survival (PFS) that is not accompanied by enhanced overall survival (OS) [26]. This dichotomy has been attributed to mechanisms of acquired re
-
br Funding br Introduction Plants absorb
2022-12-09

Funding Introduction Plants absorb both inorganic nitrogen (ammonium and nitrate) and organic nitrogen (amino acids and peptides) from the soil [1]. The first organic nitrogenous molecule produced from inorganic nitrogen is Gln, whose terminal amino group is successively transferred to make Gl
-
Aberrant lipid levels are associated with various
2022-12-09

Aberrant lipid levels are associated with various disorders, including vascular diseases and diabetes. Furthermore, important events support the idea that lipids, especially cholesterol and its derivatives, have a fundamental role in the physiopathology of AD. The GW311616 hydrochloride mg is rich
-
BAMB-4 It was also shown that of crizotinib
2022-12-09

It was also shown that 15% of crizotinib resistance mechanisms can be due to an amplification of ALK gene while 30% are caused by a variety of secondary mutations (S1206Y, G1202R, L1196M, C1156Y, G1269A, L1152R, F1174L and 1151Tins) in ALK tyrosine kinase. These mutations can modify the conformation
-
br Current therapies for metabolic diseases Inborn errors of
2022-12-09

Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
In a recent series of studies from
2022-12-09

In a recent series of studies from our laboratory, to characterize the contractile systems within the rat Stiripentol wall, three conditions were identified that led to detrusor activity: spontaneous micro-contractions, electrical field stimulated (EFS) contractions and muscarinic agonist induced c
-
Genetic observations from these studies
2022-12-08

Genetic observations from these studies suggest that GMF regulates Arp2/3 complex and UNC669 dynamics in vivo13, 14. Budding yeast Gmf1 localizes to cortical actin patches, sites of endocytosis assembled by Arp2/3 13, 14. Furthermore, deletion of GMF1 exacerbates the growth defects of a cof1-22 mut
-
CZC-25146 Based on the improved characteristics of the
2022-12-07

Based on the improved characteristics of the mutant ECDs we proceeded to crystallization trials, starting with the β1-BPloop as the most promising. We obtained rod shaped hexagonal crystals reproducibly, but with moderate diffraction ability (Fig. 5). Furthermore, the crystals were sensitive in moun
-
Very recently Niessen et al
2022-12-07

Very recently, Niessen et al. have described the resensitizing effect of MB327 on nAChR performing solid-supported membrane (SSM)-based electrophysiological experiments (Niessen et al., 2016) using plasma membrane preparations obtained from Torpedo californica. These findings validated and underline
-
In this scenario the receptor tyrosine kinase
2022-12-06

In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; PCZC-25146 mg
15686 records 352/1046 page Previous Next First page 上5页 351352353354355 下5页 Last page